Results 231 to 240 of about 113,188 (264)

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Annals of Oncology, 2018
Mariano Provencio, Pier Luigi Zinzani, Tadeusz Robak   +2 more
exaly  

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Molecular Therapy, 2017
Tanya Siddiqi, Nancy L Bartlett, Armin Ghobadi   +2 more
exaly  

CD19 regulates B lymphocyte responses to transmembrane signals

Seminars in Immunology, 1998
Manabu Fujimoto, Jonathan Poe, Thomas Tedder   +2 more
exaly  

CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer

Cancer Immunology, Immunotherapy, 2018
Yiwei Wang, Jiejie Xu, Qi Jiang
exaly  

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

Molecular Pharmaceutics, 2019
Paul Rennert, Justin R Klesmith, Benjamin Hackel   +2 more
exaly  

ANTIBODIES BINDING TO CD3 AND CD19

2021
FREIMOSER-GRUNDSCHOBER ANNE, GONZALEZ NICOLINI MARIA VALERIA, HOSSE RALF, KNAUPP ALEXANDER, MOESSNER EKKEHARD, RICHTER WOLFGANG, TROCHANOWSKA HALINA, UMAÑA PABLO, KLEIN CHRISTIAN, WALDHAUER INJA   +9 more
openaire   +3 more sources

Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis

Cell
Ling Ying Ye, Le-Hang Guo, Hongjuan Lu
exaly  

Diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19+ tumors

Molecular Oncology, 2017
Christene A Huang, Zhirui Wang, Zhaohui Wang   +2 more
exaly  

Beyond CD19

Advances in Oncology
Erin E. Doherty, Helen E. Heslop
openaire   +1 more source

An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis

Cell
Le-Hang Guo
exaly